ScripSubgroup data from ProKidney’s Phase II REGEN-007 study of rilparencel in patients with chronic kidney disease (CKD) and type 2 diabetes have encouraged the company to try and use an ongoing Phase III
ScripActithera has raised $75.5m in a series A financing to develop radioligand therapies (RLTs) that use a covalent drug design to prolong their effects on cancer cells. The early-stage company’s lead can
ScripFrontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,
ScripIn a momentous moment for the fight against malaria, Novartis has gained approval for a drug to treat the potentially deadly mosquito-borne disease in babies and very young children. Novartis, which b